Company: LNAI
Filing Date: 2025-07-30
Form Type: DEF 14A
Source: 0001731122-25-001053
Chunk: 26

Company: Lunai Bioworks Inc.
Filing Date: 2025-07-30
Form: DEF 14A
Chunk 26
---
 under
the section of this proxy statement titled “Where You Can Find More Information”.

The Company

Renovaro Inc.

2080 Century Park East, Suite 906 Los Angeles, CA 90067

(305) 918-1980

<div align='center'>17

MARKET PRICE AND DIVIDEND INFORMATION</div>

The Common Stock trades on
Nasdaq under the symbol “RENB”. As of July 15, 2025, the last full trading day immediately preceding record date for
voting on the Reverse Split Proposal, the closing price of the Common Stock as reported on Nasdaq was $0.28 per share.

As of July 15, 2025, the Record
Date for the Special Meeting, there were approximately 222 holders of record of the Common Stock. The number of record holders was determined
from the records of our transfer agent and does not include beneficial owners of our Common Stock whose shares are held in the names of
various banks, brokers or other nominees.

Assuming approval of the
Reverse Split Proposal, the Common Stock is expected to continue trading on Nasdaq under the symbol “RENB.”

Dividends

Renovaro has not declared
or paid any cash dividends on the Common Stock and does not intend to declare or pay any cash dividends in the foreseeable future. The
payment of dividends, if any, is within the discretion of the Renovaro Board and will depend on Renovaro’s earnings, if any, its
capital requirements and financial condition and such other factors as the Renovaro Board may consider.

<div align='center'>18

RISK FACTORS</div>

In addition to the other information contained in this proxy statement, you should carefully consider the material risks described below before deciding how to vote your shares of Common Stock. You should also read and consider the risks associated with the business of Renovaro because these risks may also affect the combined company—these risks can be found in the Renovaro 2024 Form 10-K and the Renovaro Third Quarter 2025 Form 10-Q, which are incorporated by reference herein. You should also read and consider the other information in this proxy statement and the other documents incorporated by reference into this proxy statement.

Summary of Risk Factors

Risks Related to Renovaro

For risks related to the business of Renovaro, please refer to the section titled “Item 1A. Risk Factors” set forth in the Renovaro 2024 Form